Minimum dose of fludarabine for the maximal modulation of 1-β-D- arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1539-1545

  Gandhi, Varsha ^a   Estey, Elihu ^a   Du, Min ^a   Keating, Michael J ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; FLUDARABINE; FLUDARABINE TRIPHOSPHATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG METABOLISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; ARABINONUCLEOTIDES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; TIME FACTORS; TUMOR STEM CELLS; VIDARABINE;

EID: 0030763113     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Keating, M. J., McCredie, K. B., Bodey, G. P., Smith, T. L., Gehan, E. A., and Freireich, E. J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. J. Am. Med Assoc 248: 2481-2486, 1982.
2. Chu, M. Y., and Fischer, G. A. Comparative studies of leukemia cells sensitive and resistant to 1-β-D-arabinofuranosylcytosine. Biochem. Pharmacol., 14: 333-341, 1965.
3. Schrecker, A. W., and Urshel, M. J. Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210: studies with intact cells Cancer Res., 28: 793-801, 1968.
4. Kantarjian, H. M., Estey, E. H., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S., McCredie, K. B., and Freireich, E. J. Phase I-II clinical and pharmacologic studies of high-dose 1-β-D-arabinofuranosylcytosine in refractory leukemia. Am. J Med 81: 387-394, 1986.
5. Estey, E., Plunkett, W., Dixon, D. O., Keating, M., McCredie, K., and Freireich, E. J. Variables predicting response to high dose 1-β-D-arabinofuranosylcytosine therapy with refractory acute leukemia. Leukemia (Baltimore). 1: 580-583, 1987.
6. Estey, E. E., Keating, M. J., McCredie, K. B., Freireich, E. J., and Plunkett, W. Cellular ara-CTP pharmacokinetics, response, and karyo-type in newly diagnosed acute myelogenous leukemia. Leukemia (Baltimore), 4: 95-99, 1990.
7. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol., 11: 116-124, 1993.
8. Gandhi, V., and Plunkett, W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells Cancer Res., 48: 329-334, 1988.
9. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Biochemical modulation of 1-β-D-arabinofuranosylcytosine for therapy of leukemias. Leukemia Lymphoma, 10 (Suppl.): 109-114, 1993.
10. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Kornblau, S., Pierce, S., Freireich, E. J., Deisseroth, A., and Keating, M. J. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol., 12: 671-678, 1994.
11. Gandhi, V., Estey, E., Du, M., Nowak, B., Keating, M. J., and Plunkett, W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin. Cancer Res., 1: 169-178, 1995.
12. Plunkett, W., Hug, V., Keating, M. J., and Chubb, S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res., 40: 588-591, 1980.
13. Gandhi, V., Danhauser, L., and Plunkett, W. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoradenine 5′-triphosphate in human leukemic cells by high performance liquid chromatography. J. Chromatogr., 413: 293-299, 1987.
14. Gandhi, V., Kemena, A., Keating, M. J., and Plunkett, W. Fludarabine infusion potentiates 1-β-D-arabinofuranosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res., 52: 897-903, 1992.
15. Liliemark, J. O., Plunkett, W., and Dixon, D. O. Relationship of 1-β-D-arabinofuranosylcytosinc in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemia cells during treatment with high-dose 1-β-D-arabinofuranosylcytosine. Cancer Res., 45: 5952-5957, 1985.
16. Plunkett, W., Liliemark, J., Estey, E., and Keating, M. J. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin. Oncol., 14 (Suppl. 1): 159-166, 1987.
17. Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H., and Keating, M. J. Saturation of 1-β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinosylcytosine therapy. Cancer Res., 47: 3005-3011, 1987.
18. Plunkett, W., Nowak, B., and Keating, M. J. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat. Rep., 71: 479-483, 1987.
19. Suki, S., Kantarjian, H., Gandhi, V., Estey, E., O'Brien, S., Beran, M., Rios, M. B., Plunkett, W., and Keating, M. J. Fludarabine and 1-β-D-arabinofuranosylcytosine in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer (Phila.), 72: 2155-2160, 1993.
20. Gandhi, V., Robertson, L. E., Keating, M. J., and Plunkett, W. Combination of fludarabine and 1-β-D-arabinofuranosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of 1-β-D-arabinofuranosylcytosine pharmacology. Cancer Chemother. Pharmacol., 34: 30-36, 1994.
21. White, E. L., Shaddix, S. D., Brockman, R. W., and Bennett, L. L., Jr. Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine on target enzymes from mouse tumor cells. Cancer Res., 42: 2260-2264, 1982.
22. Tseng, W-C., Derse, D., Cheng, Y-C., Brockman, R. W., and Bennett, L. L., Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol., 21: 474-477, 1982.
23. Sato, A., Montgomery, J. A., and Cory, J. G. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3,a]imidazole. Cancer Res., 44: 3286-3290, 1984.
24. Parker, W. B., Bapat, A. K., Shen, J-X., Townsend, A. J., and Cheng, Y-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol., 34: 485-491, 1988.
25. Parker, W. B., Shaddix, S. C., Chang, C-H., White, E. C., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A., Secrist, J. A., III, and Bennett, L. L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
26. Kemena, A., Fernandez, M., Bauman, J., Keating, M. J., and Plunkett, W. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin. Chim. Acta. 200: 95-106, 1991.
27. Avramis, V. I., Champagne, J., Sato, J., Krailo, M., Ettinger, L. J., Poplack, D. G., Finklestein, J., Reaman, G., Hammond, G. D., and Holcenberg, J. S. Pharmacology of fludarabine phosphate after a Phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res., 50: 7226-7231, 1990.
28. Plunkett, W., Chubb, S., Alexander, L., and Montgomery, J. A. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res., 40: 2349-2355, 1980.
29. Brockman, R. W., Cheng, Y-C., Schabel, F. M., and Montgomery, J. A. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res., 40: 3610-3615, 1980.
30. Kemena, A., Gandhi, V., Shewach, D., Keating, M., and Plunkett, W. Inhibition of fludarabine metabolism by 1-β-D-arabinofuranosylcytosine during therapy. Cancer Chemother. Pharmacol., 31: 193-199, 1992.
31. Krenitsky, T. A., Tuttle, J. V., Koszalka, C. W., Chen, I. S., Beacham, L. M., Rideout, J. L., and Elion, G. B. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J. Biol. Chem., 251: 4055-4061, 1976.
32. Shewach, D. S., Reynolds, K. K., and Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol., 42: 518-524, 1992.
33. Danhauser, L., Plunkett, W., Keating, M., and Cabanillas, S. 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol., 18: 145-152, 1986.
34. Malspeis, L., Grever, M. R., Staubus, A. E., and Young, D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the Phase I clinical investigation of fludarabine phosphate. Semin. Oncol., 17 (Suppl. 8): 18-32, 1990.
35. Herzig, R. H., Wolff, S. N., Lazarus, H. M., Phillips, G. L., Karanes, C., and Herzig, G. P. High-dose 1-β-D-arabinofuranosylcytosine therapy for refractory leukemia. Blood, 62: 361-369, 1983.
36. Estey, E. E., Plunkett, W., Kantarjian, H., Rios, M. B., and Keating, M. J. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leukemia Lymphoma, 10 (Suppl.): 115-122, 1993.
37. Warrell, R. P., and Berman, E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol., 4: 74-79, 1986.
38. Spriggs, D. R., Stopa, E., and Mayer, R. J. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res., 46: 5953-5958, 1986.
39. Estey, E., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., and Keating, M. J. Fludarabine and 1-β-D-arabinofuranosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma, 9: 343-350, 1993.
40. Visani, G., Tosi, P., Zinzani, P. L., Manfroi, S., Ottaviam, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberi, B., Carrara, P., Gobbi, M., and Tura, S. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of "poor-risk" acute myeloid leukemia. Leukemia (Baltimore). 8: 1842-1846, 1994.
41. Kornblau, S. M., Cortes-Franco, J., and Estey, E. Neurotoxicity associated with fludarabine and 1-β-D-arabinofuranosylcytosine chemotherapy for acute leukemia and myelodysplasia. Leukemia (Baltimore), 7: 378-383, 1993.